Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
www.touchderma.com
CONFERENCE HUB
Start Learning
Encouraging results for topical 1.5% ruxolitinib cream in milder cases of hidradenitis suppurativa
Dr Raj Chovatiya (Associate Professor at Rosalind Franklin University Chicago, IL, USA) at the 2025 American Academy of Dermatology (AAD) Annual Meeting to discuss key late-breaking data on three promising therapies—ESK001, icotrokinra, and rocatinlimab—for psoriasis and atopic dermatitis.
CONFERENCE HUB
Start Learning
#AAD25: Essential updates in atopic dermatitis and psoriasis
oral lichen planus
JOURNALS
Start Learning
New data in oral lichen planus shows LP-310 oral tacrolimus reduces pain, ulceration and inflammation
touchMEETING HIGHLIGHTS
Start Learning
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
Sponsored content
JOURNALS
Start Learning
Introducing our newest Expert Faculty member: A leader in urticaria, drug allergies and angioedema
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of CSU
Sponsored content
touchFOCUS
Start Learning
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
CE/CME ACCREDITED
Layer of cells, human skin cells, medical illustration
JOURNALS
Start Learning
Could dupilumab help improve height in children with severe atopic dermatitis?
CONFERENCE HUB
Start Learning
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria

to view Favourites, Keep Notes and Track CME Credits

Favourites
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
View
Pooled phase III data reinforce dupilumab’s efficacy in H1-antihistamine refractory chronic spontaneous urticaria
View
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
View
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
View
Rapid and significant improvements observed with topical ruxolitinb in cutaneous lichen planus
View
Novel, oral TYK2 inhibitor, ESK-001, reports improved efficacy with prolonged use in plaque psoriasis
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
BEACON study: Initial findings indicate briquilimab provides rapid and effective relief in chronic spontaneous urticaria
View
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
View
Encouraging results for topical 1.5% ruxolitinib cream in milder cases of hidradenitis suppurativa
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup